RecruitingPhase 4NCT07753720

Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction

Efficacy of Daily 5-mg Tadalafil as Adjunctive Therapy Versus Monotherapy in Men With On-Demand PDE5 Inhibitor-Resistant Erectile Dysfunction: A Prospective Randomized Trial

Sponsor

Al-Azhar University

Enrollment

260 participants

Start Date

Aug 13, 2026

Study Type

INTERVENTIONAL

Conditions

Erectile Dysfunction Tadalafil

Summary

This randomized trial will compare daily tadalafil 5 mg as adjunct therapy versus monotherapy in men with on-demand PDE5 inhibitor-resistant erectile dysfunction. The study will evaluate changes in erectile function, treatment satisfaction, partner satisfaction, and safety over 12 weeks.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Tadalafil 5 mg and a drug called Tadalafil; Current on-demand PDE5 inhibitor for people with erectile dysfunction and tadalafil. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTadalafil; Current on-demand PDE5 inhibitor

Tadalafil 5 mg orally once daily for 12 weeks plus the participant's current effective on-demand PDE5 inhibitor, taken 1-2 hours before sexual activity, with a maximum of once daily.

DRUGTadalafil 5 mg

Tadalafil 5 mg orally once daily for 12 weeks.